N/A N=54 Recurrent Bacterial Vaginosis and Vaginal Acidifying Gel Trial
Bacterial Vaginosis
Primary: Recurrent Bacterial Vaginosis — 7; 7 Participants — p=0.75
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=1,365 Bacterial Vaginosis Home Screening to Prevent STDs
Bacterial Vaginosis
Primary: One-year Incidence of Chlamydial and Gonococcal Infections in Women Who Receive Screening (Every 2 Months) and Treatment for Asymptomatic Bacterial Vaginosis as Compared…
Phase 3 N=251 A Phase 3 Study of SPL7013 Gel (VivaGel) for the Treatment of Bacterial Vaginosis
Bacterial Vaginosis
Primary: Number of Women With Clinical Cure at the End of Treatment Visit (EOT) — 68; 25 Participants — p=<0.001
Phase 3 N=250 A Phase 3 Study of SPL7013 Gel (VivaGel) for the Treatment of Bacterial Vaginosis
Bacterial Vaginosis
Primary: Number of Women With Clinical Cure at the End of Treatment Visit (EOT) — 59; 19 Participants — p=<0.001
N/A N=35 Study of How Bacterial Vaginosis and Its Treatment Affects Cervical and Vaginal Tissue
Bacterial Vaginosis · Vaginal Discharge
Primary: p24 Antigen Production in Tissue
Phase 4 N=126 Probiotics as Adjuvant Treatment for Bacterial Vaginosis
Bacterial Vaginosis
Primary: Number of Participants With Related Clinical Signs or Symptoms at Baseline — 63; 63 Participants — p=<0.01
Phase 2 N=215 A Phase 2 Study of SYM-1219 to Treat Bacterial Vaginosis
Bacterial Vaginosis
Primary: Cure of Bacterial Vaginosis — 33; 42; 11; 31 Participants
Phase 4 N=593 Treatment of Bacterial Vaginosis (BV) With Tinidazole
Bacterial Vaginosis
Primary: Cure of Bacterial Vaginosis — 75; 73; 77 participants
Phase 2 N=81 Suppression Of Bacterial Vaginosis (BV) [SUBVert]
Bacterial Vaginosis
Primary: Proportion of Participants With Recurrent Bacterial Vaginosis (RBV) by Visit 4, as Defined by Presence of at Least 3 Amsel Criteria — 0.581; 0.697 proportion of…
Phase 4 N=12 Asymptomatic Bacterial Vaginosis and Herpes Simplex Virus Type 2 (BV/HSV-2) Shedding Study
Bacterial Vaginosis
Primary: Number of Participants With Bacterial Vaginosis Recurrence — 8 Participants
Phase 3 N=189 A Phase 3 Study of SYM-1219 Treatment of Women and Post-Menarchal Adolescent Girls With Bacterial Vaginosis
Bacterial Vaginosis
Primary: Clinical Outcome Responder Rate — 57; 11; 50; 46 Participants
Phase 2 N=228 LACTIN-V Study for Recurrent Bacterial Vaginosis
Bacterial Vaginosis
Primary: The Proportion of Participants Reporting Product-related Adverse Events (AEs) and Serious Adverse Events (SAEs) in Each Study Arm. — 0.11; 0.07 proportion of…
N/A N=24 Clinical Performance of a Vaginal Pessary (pHyph) in Bacterial Vaginosis
Bacterial Vaginosis
Primary: Clinical Cure Rate — 18 Participants
Phase 2 N=132 Dose Ranging Study of SPL7013 Gel for Treatment of Bacterial Vaginosis (BV)
Bacterial Vaginosis
Primary: Number of Women With Clinical Cure as a Measure of Efficacy — 7; 12; 7; 3 Participants — p=0.006
Phase 3 N=184 Trial of Trimosan Gel Effect on Pessary-associated Bacterial Vaginosis
Bacterial Vaginosis
Primary: Number of Patients With Bacterial Vaginosis at 3 Months — 15; 16 Participants
Phase 2 N=109 Safety and Efficacy of 5% Monolaurin Vaginal Gel Administered Intravaginally for the Treatment of Bacterial Vaginosis
Bacterial Vaginosis
Primary: Number of Participants With Clinical Cure in Each Study Arm — 11; 8 Participants — p=0.420
Phase 3 N=586 Efficacy and Safety Study of SPL7013 Gel to Prevent the Recurrence of Bacterial Vaginosis (BV)
Bacterial Vaginosis
Primary: Recurrence of BV Where a Diagnosis of BV is Defined as the Presence of at Least 3 Clinical Findings — 130; 158 Participants — p=0.015
Phase 3 N=24 Suppressive Antibacterial Therapy With Once-Weekly Secnidazole Granules to Prevent Recurrent Bacterial Vaginosis; A Pilot Study
Recurrent Bacterial Vaginosis
Primary: Number of Subjects With at Least One Episode of Bacterial Vaginosis — 8 Participants
Phase 3 N=307 DARE-BV1 in the Treatment of Bacterial Vaginosis (DARE-BVFREE)
Bacterial Vaginosis
Primary: Number of Patients With Clinical Cure at the TOC Visit (Day 21-30). — 86; 21 Participants
Phase 3 N=871 Study Evaluating the Equivalence of GDC-229 and Metronidazole Vaginal Gel 0.75% in the Treatment of Bacterial Vaginosis
Bacterial Vaginosis
Primary: Clinical Cure — 135; 129; 74 Participants — p=<0.001
Phase 2 N=234 Topical Metronidazole and Miconazole Co-formulated Vaginal Suppositories for Preventing Vaginal Infections in HIV-seronegative Women
Bacterial Vaginosis · Candidiasis · Trichomoniasis
Primary: Efficacy of Monthly Periodic Presumptive Treatment (PPT) Using Metronidazole With Miconazole Intravaginal Suppositories Versus Matching Placebo Nightly for Five Nights…
Phase 3 N=214 Randomized Controlled Trial of Treatment of Male Partners of Women With BV
Recurrent Bacterial Vaginosis
Primary: Number of Female Partners Whose Male Partners Received Metronidazole Versus Females Whose Male Partners Did Not Receive Metrodiazole With Recurrence of BV in the Female…
Phase 4 N=48 Use of Boric Acid in Combination With Probiotics for the Treatment of Vaginal Infections
Candidiasis · Vaginosis, Bacterial
Primary: Change in the Presence of Vaginitis Clinical Symptoms Determined by Sobel Score. — 1.13; 1.21; 0.18; 0.22 score on a scale
Phase 2 N=97 Treatment of Gardnerella Vaginalis Vaginal Colonization With Amoxicillin
Vaginitis Gardnerella
Primary: The Proportion of Participants With Eradication of Gardnerella Vaginalis (GV) in Each Study Arm at Visit 2 (Day 15-21) as Assessed by Nucleic Acid Amplification Test…
Phase 3 N=604 A Multi-center, Double-blind, Randomized Study, Comparing Clindamycin Phosphate Vaginal Cream 2% (Watson Laboratories, Inc.) to Clindesse® (Ther-Rx™, Clindamyin Phosphate Vaginal Cream 2%) and Both Active Treatments to a Placebo Control in the Treatment of Bacterial Vaginosis in Non-pregnant Women
BACTERIAL VAGINOSIS · Signs and Symptoms to be Evaluated and Recorded Include · Vaginal Discharge Color, Odor, and Consistency
Primary: Number of Participants With Both a Clinical and a Bacteriological Cure (Nugent Score <4), Evaluated at Visit 2 Test-of-cure (Study Day 22-30). — 36; 34; 9 Participants
N/A N=68 Rwanda Vaginal Microbiota Restoration Study
Bacterial Vaginosis
Primary: Bacterial Vaginosis (BV) Incidence by Modified Amsel Criteria — 7.53; 2.04; 3.36; 3.35 Incidence: events per PY at risk
N/A N=519 A Validation Study of Genzyme Diagnostics OSOM Trichomonas Rapid Test and BVBlue Test
Bacterial Vaginosis · Urogenital Infection by Trichomonas Vaginalis
Primary: Sensitivity of the OSOM Rapid Test and PCR Wet Mount Microscopy in Diagnosing Trichomonas Vaginalis in Symptomatic and Asymptomatic Women — 92; 91; 100; 100 Percentage…
Phase 4 N=28 Examining the Impact of Tampon Use on the Vaginal Microbiota
Vaginal Microbiota
Primary: Change in Relative Abundance of Lactobacillus Species — .0084; -.0014; -.00004; .0104 relative abundance
Phase 3 N=160 A Study to Compare Efficacy and Safety of an Ovule Containing Terconazole, Clindamycin and Fluocinolone Versus an Ovule Containing Metronidazole, Nystatin and Fluocinolone in the Treatment of Secondary Vulvar/ or Vaginal Symptoms of Infectious Vaginitis/ and Infectious Vaginosis
Vaginitis · Infectious Vaginosis
Primary: Percentage of Participants With Presence or Absence of Symptoms 3 Days After Treatment — 67.1; 79.2; 32.9; 20.8 Percentage of Participants
Phase 3 N=204 Multi-Center Study of New Medications to Treat Vaginal Infections
Vaginal Infection
Primary: Clinical Cure as Assessed by the Investigator at the Test-of-cure Visit — 47; 18 Participants — p=<0.001